Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL117566 | 0.87 | CRBN (0.41) | CRBNDDB1CACNA1FALDH1A1MAPT | |
| SCHEMBL2201251 | 0.81 | CRBN (0.38) | CRBNDDB1PDE7A | |
| Hydrochloric Acid SCHEMBL21292655 | 0.80 | CRBN (0.37) | CRBNDDB1PDE7A | |
| SCHEMBL24535197 | 0.78 | PDE7A (0.38) | CRBNPDE7A | |
| SCHEMBL3332022 | 0.78 | PDE7A (0.38) | CRBNPDE7A | |
| SCHEMBL8775591 | 0.78 | — | — | |
| SCHEMBL239415 | 0.75 | CRBN (0.41) | CRBNDDB1PDE7A | |
| SCHEMBL21357275 | 0.74 | CRBN (0.36) | CRBNDDB1CACNA1FALDH1A1MAPT | |
| SCHEMBL542497 | 0.74 | PDE7A (0.47) | CRBNPDE7A | |
| SCHEMBL630549 | 0.74 | CRBN (0.43) | CRBNDDB1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4600247-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-118084940-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112041311-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-4227302-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4208461-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2023-07-12 | — | — | EP | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11555029-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| EP-2595969-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555029-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | CRBN 1103/4885DDB1 83/4885CACNA1F 4688/4885 |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CRBN 1103/4885DDB1 83/4885CACNA1F 4688/4885 |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | CRBN 1103/4885DDB1 83/4885CACNA1F 4688/4885 |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | CRBN 3991/4885DDB1 2048/4885CACNA1F 1050/4885 |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CRBN 1103/4885DDB1 83/4885CACNA1F 4688/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CRBN 1103/4885DDB1 83/4885CACNA1F 4688/4885 |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | CRBN 3419/4885DDB1 3787/4885CACNA1F 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.